Chimeric Therapeutics Limited (CHMMF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerChimeric Therapeutics Limited (CHMMF) trades at $0.10. Chimeric Therapeutics Limited is an Australian clinical-stage cell therapy company focused on developing and commercializing innovative oncology treatments. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for CHMMF: CHMMF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CHMMF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
These figures come from statements filed 14 months ago — the most recent this company has published.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
CHMMF: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Chimeric Therapeutics Limited (CHMMF) Healthcare & Pipeline Overview
Chimeric Therapeutics Limited is an Australian clinical-stage biotechnology company specializing in cell therapies for oncology, with a focus on CAR-T and NK cell platforms. Their pipeline targets both solid tumors and hematological malignancies, positioning them in the competitive and rapidly evolving cell therapy landscape.
What Is the Investment Thesis for CHMMF?
Chimeric Therapeutics presents a high-risk, high-reward investment opportunity within the burgeoning field of cell therapy. The company's focus on both CAR-T and NK cell platforms offers diversification in a rapidly evolving technological landscape. The ongoing Phase I clinical trials for CHM 1101 and CHM 0201 represent key catalysts for potential value appreciation. Positive clinical data from these trials could significantly boost investor confidence and attract partnerships. However, the company's negative profit margin of -420.8% and reliance on future funding pose significant risks. Successful navigation of clinical trials, regulatory hurdles, and manufacturing scalability will be crucial for realizing the company's potential. Monitoring the progress of clinical trials and the company's cash runway is essential for assessing the investment viability.
Based on FMP financials and quantitative analysis
CHMMF Key Highlights
Chimeric Therapeutics is a clinical-stage cell therapy company focused on oncology, developing both CAR-T and NK cell therapies.
- The company's lead asset, CHM 1101 (CLTX CAR T), is in Phase I clinical trials for MMP2+ recurrent or progressive glioblastoma.
- CHM 0201, Chimeric's core NK platform, is also in Phase I clinical trials, targeting solid tumors and hematological malignancies.
- Chimeric Therapeutics has a negative profit margin of -420.8%, indicating significant ongoing investment in research and development.
- The company's gross margin is 74.5%, suggesting potential for profitability upon successful commercialization of its therapies.
Who Are CHMMF's Competitors?
CHMMF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BETRF BetterLife Pharma Inc. | $0.23 | +4.11% | $36.5M | — |
| CUBT Curative Biotechnology, Inc. | $1.00 | +33.33% | $6.82M | — |
| GLWLF Glow Lifetech Corp. | $0.03 | -8.16% | $5.54M | — |
| LIANY LianBio | $0.05 | -5.53% | $5.35M | — |
| NVO Novo Nordisk A/S | $44.01 | -1.23% | $195B | 925-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $514.90 | +0.07% | $131B | 965-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $793.26 | -1.78% | $81.7B | 945-pillar |
| ARGX argenx SE | $984.04 | -1.82% | $61.2B | 975-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CHMMF's Key Strengths?
Proprietary CAR-T and NK cell therapy platforms.
- Pipeline of clinical-stage assets targeting various cancers.
- Experienced management team with expertise in cell therapy development.
- Strong intellectual property portfolio.
What Are CHMMF's Weaknesses?
Limited financial resources and reliance on future funding.
- Early stage of clinical development with significant regulatory hurdles.
- High risk of clinical trial failure.
- Competition from established pharmaceutical companies and other biotech firms.
What Could Drive CHMMF Stock Higher?
CHMMF catalyst: Publication of interim data from Phase I clinical trials for CHM 1101 (CLTX CAR T) in 2026.
- Initiation of Phase II clinical trials for CHM 1101 in 2027, contingent on positive Phase I results.
- Enrollment and progress in Phase I clinical trials for CHM 0201 (core NK platform).
- Research and development efforts focused on next-generation cell therapy technologies.
- Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
What Are the Key Risks for CHMMF?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays, which could significantly impact the company's valuation.
- Regulatory setbacks or changes in approval requirements for cell therapies.
- Competition from established pharmaceutical companies and other biotech firms developing similar therapies.
- Limited financial resources and reliance on future funding to support clinical development.
- Risks associated with manufacturing and scaling up cell therapy production.
What Are the Growth Opportunities for CHMMF?
- Expansion of Clinical Trials: A significant growth opportunity lies in expanding the clinical trials for CHM 1101 and CHM 0201 to later phases and additional indications. Positive data from these trials could lead to accelerated regulatory approval and commercialization. The market for glioblastoma treatment, for example, is substantial, with limited effective therapies currently available. Success in this area could generate significant revenue streams for Chimeric Therapeutics. The timeline for this growth opportunity is dependent on the progress of the ongoing Phase I trials and subsequent funding.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions represents another key growth opportunity. Collaborations can provide access to additional funding, expertise, and resources, accelerating the development and commercialization of Chimeric's cell therapies. These partnerships could also facilitate expansion into new geographic markets. The timeline for securing such partnerships is uncertain but could materialize within the next 1-3 years.
- Development of Next-Generation Cell Therapies: Investing in the development of next-generation cell therapies, such as allogeneic CAR-T or enhanced NK cell platforms, could provide a competitive edge. These advanced therapies may offer improved efficacy, safety, and scalability compared to current approaches. The timeline for developing and testing these next-generation therapies is likely to be 3-5 years, requiring significant ongoing research and development investment.
- Geographic Expansion: Expanding operations beyond Australia into key markets such as the United States and Europe represents a significant growth opportunity. These markets offer larger patient populations and greater potential for revenue generation. However, geographic expansion requires significant investment in infrastructure, regulatory compliance, and commercialization efforts. The timeline for this expansion is likely to be 2-4 years, contingent on securing adequate funding and regulatory approvals.
- Targeting New Cancer Indications: Expanding the pipeline to target new cancer indications beyond glioblastoma and hematological malignancies represents another growth opportunity. Identifying and validating novel targets for cell therapy in other solid tumors could significantly broaden the company's market potential. This expansion requires ongoing research and development efforts to identify and validate new targets. The timeline for this growth opportunity is likely to be 3-5 years, dependent on research progress and funding availability.
What Are CHMMF's Competitive Advantages?
- Proprietary cell therapy technologies, including CAR-T and NK cell platforms.
- Intellectual property protection through patents and other forms of exclusivity.
- Clinical data demonstrating the safety and efficacy of its therapies.
- Expertise in cell therapy development and manufacturing.
What Does CHMMF Do?
Chimeric Therapeutics Limited, incorporated in 2020 and based in Carlton, Australia, is a clinical-stage cell therapy company dedicated to developing and commercializing innovative cell therapies for cancer treatment. The company's primary focus is on harnessing the power of cell-based immunotherapies, specifically CAR-T (Chimeric Antigen Receptor T-cell) and NK (Natural Killer) cell therapies, to target and eradicate cancer cells. Their pipeline includes several promising candidates in various stages of clinical development. Chimeric's lead assets include CHM 1101 (CLTX CAR T), currently in Phase I clinical trials for patients with MMP2+ recurrent or progressive glioblastoma, a particularly aggressive form of brain cancer. Additionally, CHM 0201, their core NK platform, is also in Phase I clinical trials, targeting both solid tumors and hematological malignancies. The company is also developing CHM 0301 for blood cancers, CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors, CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics aims to address unmet medical needs in oncology by developing novel and effective cell therapies. The company's strategic focus on both CAR-T and NK cell platforms provides diversification and allows them to explore the potential of different cell types in cancer immunotherapy. While still in the early stages of clinical development, Chimeric Therapeutics is positioning itself as a key player in the rapidly evolving field of cell therapy.
What Products and Services Does CHMMF Offer?
- Develops cell therapies for oncology.
- Focuses on CAR-T (Chimeric Antigen Receptor T-cell) therapies.
- Develops NK (Natural Killer) cell therapies.
- Conducts Phase I clinical trials for CHM 1101 (CLTX CAR T) targeting glioblastoma.
- Conducts Phase I clinical trials for CHM 0201 (core NK platform) targeting solid tumors and hematological malignancies.
- Develops CHM 0301 for blood cancers.
- Develops CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors.
- Develops CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric cancers.
How Does CHMMF Make Money?
- Develops and patents novel cell therapy technologies.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval for its therapies.
- Aims to commercialize its therapies through direct sales or partnerships.
What Industry Does CHMMF Operate In?
Chimeric Therapeutics operates within the dynamic and competitive biotechnology industry, specifically in the rapidly evolving field of cell therapy. The competitive landscape includes established pharmaceutical companies and specialized biotech firms, all vying for market share. Chimeric Therapeutics is positioning itself by focusing on both CAR-T and NK cell platforms, aiming to differentiate itself through novel targets and improved efficacy and safety profiles. Success in this industry requires significant investment in research and development, navigating complex regulatory pathways, and establishing robust manufacturing capabilities.
Who Are CHMMF's Key Customers?
- Patients with cancer, particularly those with glioblastoma, hematological malignancies, and solid tumors.
- Hospitals and cancer treatment centers.
- Oncologists and other healthcare professionals.
- Potential pharmaceutical partners for licensing or co-development agreements.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 438 days ago
- ● No analyst coverage
- ● Reported in AUD, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 56 |
| 2026-08-26 | 56 |
| 2026-08-29 | 56 |
| 2026-09-01 | 56 |
| 2026-09-04 | 56 |
| 2026-09-07 | 56 |
| 2026-09-10 | 56 |
What changed?
The score has stayed at 56.
Over the same 18 days the stock moved +0.0%.
Chimeric Therapeutics Limited Financial Trajectory
Chimeric Therapeutics Limited (CHMMF) reported $5.1M in revenue for Q4 FY2025, reflecting 28.4% growth compared to the prior quarter. The company recorded a net loss of $5.4M, with diluted EPS of $-0.32.
Company Profile
Chimeric Therapeutics Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Carlton, Australia.
Financial Health
Chimeric Therapeutics Limited's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Earnings Track Record
Chimeric Therapeutics Limited has beaten Wall Street's EPS estimate in 3 of its last 4 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 26.9% above estimates on average.
Forward Outlook
Wall Street analysts project Chimeric Therapeutics Limited revenue of about $378.7M for fiscal 2026, with EPS near $0.00.
CHMMF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Proprietary CAR-T and NK cell therapy platforms.
- Pipeline of clinical-stage assets targeting various cancers.
- Experienced management team with expertise in cell therapy development.
- Strong intellectual property portfolio.
Bear Case
- Limited financial resources and reliance on future funding.
- Early stage of clinical development with significant regulatory hurdles.
- High risk of clinical trial failure.
- Competition from established pharmaceutical companies and other biotech firms.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 FY2025 | $5M | -$5M | -$0.32 |
| Q2 FY2025 | $4M | -$2M | -$0.20 |
Q4 FY2025 · filed 30 Jun 2025 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from AUD at today's rate
CHMMF Latest News
No recent news available for CHMMF.
CHMMF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CHMMF.
Price Targets
Wall Street price target analysis for CHMMF.
CHMMF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CHMMF; grades run from A+ (80-100) to F (below 30).
Leadership: Rebecca McQualter
CEO
Rebecca McQualter is the Chief Executive Officer of Chimeric Therapeutics. Her background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on strategic leadership and business development. She has held various leadership roles in companies focused on oncology and cell therapy, bringing a wealth of knowledge to Chimeric Therapeutics. Her expertise spans from early-stage research and development to commercialization strategies.
Track Record: Under Rebecca McQualter's leadership, Chimeric Therapeutics has advanced its clinical pipeline, including the progression of CHM 1101 and CHM 0201 into Phase I clinical trials. She has also overseen the expansion of the company's research and development efforts, focusing on next-generation cell therapy technologies. Her strategic decisions have been instrumental in securing funding and establishing partnerships to support the company's growth.
CHMMF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Chimeric Therapeutics may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier is generally associated with higher risk due to the potential for less transparency and liquidity.
- OTC Tier: OTC Other
- Limited liquidity and wider bid-ask spreads.
- Less stringent regulatory oversight and disclosure requirements.
- Potential for price volatility and manipulation.
- Higher risk of fraud or mismanagement compared to listed companies.
- Difficulty in obtaining reliable financial information.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements and assess its financial health.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the company's intellectual property and patent protection.
- Monitor news and announcements related to the company.
- Consult with a qualified financial advisor before investing.
- Clinical-stage development of CAR-T and NK cell therapies.
- Experienced management team with expertise in cell therapy.
- Intellectual property portfolio with patents and other forms of exclusivity.
- Ongoing Phase I clinical trials for CHM 1101 and CHM 0201.
- Focus on addressing unmet medical needs in oncology.
What Investors Ask About Chimeric Therapeutics Limited (CHMMF) — Healthcare
Is CHMMF a good stock?
Stock Expert AI does not rate CHMMF buy, sell or hold. Chimeric Therapeutics Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about CHMMF stock?
As of March 17, 2026, there is no available analyst coverage for CHMMF. Given its OTC listing and early-stage clinical development, comprehensive analyst reports may be limited.
What are the key factors to evaluate for CHMMF?
Evaluate CHMMF on fundamentals, analyst consensus, and risk factors. The ongoing Phase I clinical trials for CHM 1101 and CHM 0201 represent key catalysts for potential value appreciation. Not financial advice.
How frequently does CHMMF data refresh on this page?
CHMMF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CHMMF's recent stock price performance?
Chimeric Therapeutics Limited (CHMMF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary CAR-T and NK cell therapy platforms. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CHMMF overvalued or undervalued right now?
Chimeric Therapeutics Limited (CHMMF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CHMMF?
Yes, most major brokerages offer fractional shares of Chimeric Therapeutics Limited (CHMMF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CHMMF's earnings and financial reports?
Chimeric Therapeutics Limited (CHMMF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for CHMMF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of March 17, 2026.
- OTC market data may have limited reliability compared to major exchanges.
- Clinical trial outcomes are inherently uncertain.